Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Last updated: March 16, 2025
Sponsor: Tanta University
Overall Status: Active - Recruiting

Phase

2

Condition

Liver Disease

Primary Biliary Cholangitis

Treatment

Carbocysteine 375 MG

Physical activity, walking, and calorie restriction

Clinical Study ID

NCT06863376
1478
  • Ages 18-65
  • All Genders

Study Summary

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Either male or female adult patients (>18 years) with fatty liver diagnosis by usingupper abdominal ultrasound echography

Exclusion

Exclusion Criteria:

  • Pregnant and/or lactating women

  • Excessive alcohol use (defined as an average alcohol intake > 30 g per day in menand > 20 g per day in women)

  • Other etiology of chronic liver diseases such as viral hepatitis, drug-inducedhepatitis, autoimmune hepatitis.

  • patients suffering from chronic kidney disease, and hyper/hypoparathyroidism

  • Hypersensitivity to carbocistiene.

Study Design

Total Participants: 46
Treatment Group(s): 2
Primary Treatment: Carbocysteine 375 MG
Phase: 2
Study Start date:
March 01, 2025
Estimated Completion Date:
April 20, 2026

Connect with a study center

  • Tanta Unuversity

    Tanta, 31527
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.